Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.

Albertsen IE, Larsen TB, Rasmussen LH, Overvad TF, Lip GY.

Drugs. 2012 Sep 10;72(13):1755-64. doi: 10.2165/11635630-000000000-00000. Review.

PMID:
22876779
2.

Pentasaccharides for the prevention of venous thromboembolism.

Dong K, Song Y, Li X, Ding J, Gao Z, Lu D, Zhu Y.

Cochrane Database Syst Rev. 2016 Oct 31;10:CD005134. Review.

PMID:
27797404
3.

Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.

Yoshida Rde A, Yoshida WB, Maffei FH, El Dib R, Nunes R, Rollo HA.

Ann Vasc Surg. 2013 Apr;27(3):355-69. doi: 10.1016/j.avsg.2012.06.010. Review.

PMID:
23351997
4.

Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.

Feng W, Wu K, Liu Z, Kong G, Deng Z, Chen S, Wu Y, Chen M, Liu S, Wang H.

Thromb Res. 2015 Dec;136(6):1133-44. doi: 10.1016/j.thromres.2015.10.009.

PMID:
26498222
5.

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators..

N Engl J Med. 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899.

6.

The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.

Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Kitt MM, Lorenz TJ.

Am Heart J. 2014 Mar;167(3):335-41. doi: 10.1016/j.ahj.2013.11.006.

7.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714.

8.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators..

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

9.

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

Clin Ther. 2007 Nov;29(11):2395-405. Review.

PMID:
18158080
10.

Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

Nieto JA, Espada NG, Merino RG, González TC.

Thromb Res. 2012 Aug;130(2):183-91. doi: 10.1016/j.thromres.2012.02.011.

PMID:
22425218
11.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Di Nisio M, Porreca E, Otten HM, Rutjes AW.

Cochrane Database Syst Rev. 2014 Aug 29;(8):CD008500. doi: 10.1002/14651858.CD008500.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 01;12 :CD008500.

PMID:
25171736
12.
13.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators., Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903.

14.

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group..

Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679.

PMID:
21225098
15.

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos A, Tapson V.

J Thromb Thrombolysis. 2011 May;31(4):407-16. doi: 10.1007/s11239-011-0549-x.

16.

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.

Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T.

J Thromb Haemost. 2015 Dec;13(12):2187-91. doi: 10.1111/jth.13153.

PMID:
26407753
18.

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.

Robertson L, Kesteven P, McCaslin JE.

Cochrane Database Syst Rev. 2015 Dec 4;(12):CD010957. doi: 10.1002/14651858.CD010957.pub2. Review.

PMID:
26636644
19.

Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

Loke YK, Kwok CS.

J Clin Pharm Ther. 2011 Feb;36(1):111-24. doi: 10.1111/j.1365-2710.2010.01162.x. Review.

PMID:
21198726
20.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group..

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

Items per page

Supplemental Content

Support Center